These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38587549)

  • 21. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
    Vadakara J; von Mehren M
    Hematol Oncol Clin North Am; 2013 Oct; 27(5):905-20. PubMed ID: 24093167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
    Schaefer IM; DeMatteo RP; Serrano C
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35522913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapeutic agents in gastrointestinal stromal tumours.
    Falkenhorst J; Hamacher R; Bauer S
    Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
    Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathology of gastrointestinal stromal tumors and implications for treatment and prognosis.
    Parkin B; Chugh R
    Curr Probl Cancer; 2011; 35(5):245-54. PubMed ID: 22118564
    [No Abstract]   [Full Text] [Related]  

  • 26. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational insights into gastrointestinal stromal tumor and current clinical advances.
    Hemming ML; Heinrich MC; Bauer S; George S
    Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.
    Vallilas C; Sarantis P; Kyriazoglou A; Koustas E; Theocharis S; Papavassiliou AG; Karamouzis MV
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application and value of mutation detection in diagnosis and treatment of gastrointestinal stromal tumor].
    Cao H; Wang M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):208-11. PubMed ID: 23536336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.
    Sankhala KK
    Expert Opin Investig Drugs; 2017 Apr; 26(4):427-443. PubMed ID: 28267385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy.
    Valsangkar N; Sehdev A; Misra S; Zimmers TA; O'Neil BH; Koniaris LG
    Surgery; 2015 Nov; 158(5):1149-64. PubMed ID: 26243346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current research and treatment for gastrointestinal stromal tumors.
    Lim KT; Tan KY
    World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
    Park SH; Ryu MH; Ryoo BY; Im SA; Kwon HC; Lee SS; Park SR; Kang BY; Kang YK
    Invest New Drugs; 2012 Dec; 30(6):2377-83. PubMed ID: 22270258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
    Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
    Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Xu J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gastrointestinal stromal tumors: a rare nosological entity and a model example for the use of personalized therapy with a molecular basis].
    Bettegazzi C; Erra S
    Recenti Prog Med; 2015 Jan; 106(1):52-7. PubMed ID: 25621782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
    J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.